v3.26.1
Consolidated Condensed Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Cash flows from operating activities:    
Net income $ 13,828 $ 6,036
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation 4,174 4,235
Amortization of deferred debt issuance costs 1,276 1,443
Amortization 14,663 14,018
Stock-based compensation 5,502 13,863
Deferred income taxes 1,535 (2,659)
Gain on sale of a product line (3,916) 0
Non-cash adjustments to fair value of contingent consideration liability 722 3,962
Increase (decrease) in cash flows from changes in assets and liabilities:    
Accounts receivable 18,606 18,984
Inventories (12,269) (7,475)
Accounts payable 10,480 (7,317)
Accrued compensation and benefits (21,153) (8,181)
Other assets (17,215) (5,422)
Other liabilities (2,761) 10,047
Net cash provided by operating activities 13,472 41,534
Cash flows from investing activities:    
Proceeds from sale of a product line 7,000 0
Purchases of property, plant and equipment (2,892) (3,779)
Other 0 850
Net cash provided by (used in) investing activities 4,108 (2,929)
Cash flows from financing activities:    
Payments on term loan 0 (14,588)
Payments on revolving line of credit (155,000) (166,000)
Proceeds from revolving line of credit 180,000 166,000
Repurchases of common stock (37,017) 0
Payments related to contingent consideration (11,364) (7,166)
Dividends paid on common stock 0 (6,180)
Other, net 828 (464)
Net cash used in financing activities (22,553) (28,398)
Effect of exchange rate changes on cash and cash equivalents (814) 819
Net increase (decrease) in cash and cash equivalents (5,787) 11,026
Cash and cash equivalents at beginning of period 40,817 24,459
Cash and cash equivalents at end of period 35,030 35,485
Non-cash financing activities:    
Dividends payable $ 0 $ 6,186